Tongyu Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tongyu Zhu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Guoyi Wu
Shanghai Public Health Clinical Center, Fudan University
2 shared publications Jiahua Huang
Department of Neurology, Zhongshan Hospital Fudan University, 170 Fenglin Road, Shanghai, 200030, China
2 shared publicationsXinyue Zhang
Shanghai Skin Disease Hospital, School of Medicine, Tongji University, 1278 Baode Road, Shanghai, 200443, China
2 shared publicationsZhiyu Qian
Department of Kidney Transplantation, Zhongshan Hospital Fudan University, 170 Fenglin Road, Shanghai, 200030, China; Shanghai key laboratory of organ transplantation, 170 Fenglin Road, Shanghai, 200030, China; Department of Urology, Huadong Hospital Fudan University, 221 West Yan'an Road, Shanghai, 200040, China
2 shared publicationsChunlan Hu
Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai, 201508, China
1 shared publicationCuisong Zhu
Shanghai Public Health Clinical Center, Fudan University, 2901 Caolang Road, Shanghai 201500, China
1 shared publication
Latest Publications
- Open Access
- 14 May 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 236, 204-219
Glucose deprivation-restoration induces labile iron overload and ferroptosis in renal tubules through V-ATPase-mTOR axis-mediated ferritinophagy and iron release by TPC2
- 14 May 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 236, 204-219
Open AccessGlucose deprivation-restoration induces labile iron overload and ferroptosis in renal tubules through V-ATPase-mTOR axis-mediated ferritinophagy and iron release by TPC2
- Open Access
- 28 May 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (23) , 24853-24863
ROS-responsive MSC-derived Exosome Mimetics Carrying MHY1485 Alleviate Renal Ischemia Reperfusion Injury through Multiple Mechanisms
Renal ischemia reperfusion (IR) injury is a prevalent inflammatory nephropathy in surgeries such as renal transplantation or partial nephrectomy, damaging renal function through inducing inflammation and cell death in renal tubules. Mesenchymal stromal/stem cell (MSC)-based therapies, common treatments to attenuate inflammation in IR diseases, fail to exhibit satisfying effects on cell death in renal IR. In this study, we prepared MSC-derived exosome mimetics (EMs) carrying the mammalian target of the rapamycin (mTOR) agonist to protect kidneys in proinflammatory environments under IR conditions. The thioketal-modified EMs carried the mTOR agonist and bioactive molecules in MSCs and responsively released them in kidney IR areas. MSC-derived EMs and mTOR agonists protected kidneys synergistically from IR through alleviating inflammation, apoptosis, and ferroptosis. The current study indicates that MSC-TK-MHY1485 EMs (MTM-EM) are promising therapeutic biomaterials for renal IR injury.
- 28 May 2024
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 9 (23) , 24853-24863
Open AccessROS-responsive MSC-derived Exosome Mimetics Carrying MHY1485 Alleviate Renal Ischemia Reperfusion Injury through Multiple Mechanisms
Renal ischemia reperfusion (IR) injury is a prevalent inflammatory nephropathy in surgeries such as renal transplantation or partial nephrectomy, damaging renal function through inducing inflammation and cell death in renal tubules. Mesenchymal stromal/stem cell (MSC)-based therapies, common treatments to attenuate inflammation in IR diseases, fail to exhibit satisfying effects on cell death in renal IR. In this study, we prepared MSC-derived exosome mimetics (EMs) carrying the mammalian target of the rapamycin (mTOR) agonist to protect kidneys in proinflammatory environments under IR conditions. The thioketal-modified EMs carried the mTOR agonist and bioactive molecules in MSCs and responsively released them in kidney IR areas. MSC-derived EMs and mTOR agonists protected kidneys synergistically from IR through alleviating inflammation, apoptosis, and ferroptosis. The current study indicates that MSC-TK-MHY1485 EMs (MTM-EM) are promising therapeutic biomaterials for renal IR injury.